Encorafenib/Binimetinib Outperforms BRAF Inhibitor Monotherapy in BRAF V600+ Melanoma
Source: Targeted Oncology, July 2022
The BRAF/MEK inhibitor combination of encorafenib (Braftovi) and binimetinib (Mekinist) has demonstrated long-term benefits in patients with BRAF V600-mutant melanoma, according to 5-year analysis results from the COLUMBUS study (NCT01909453). The safety profile of the combination was also consistent with prior reports, according to the published findings.
“COLUMBUS long-term follow-up data continue to support the short and long-term benefit of this BRAF/MEK regimen for patients who receive this treatment as the first therapy for metastatic melanoma. We knew based on the shorter follow-up data that this regimen is uniquely well-tolerated, and this long-term data reinforces that point, Keith Flaherty, MD, director of clinical research at Massachusetts General Cancer Center and co-investigator of COLUMBUS told Targeted Oncology™, in an interview.
Encorafenib plus binimetinib achieved a median progression-free survival (PFS) of 14.9 months (95% CI, 11.0-20.2 months) vs 7.3 months (95% CI, 11.0-7.9 months) in the vemurafenib monotherapy arm (HR 0.51; 95% CI, 0.40-0.67). In the encorafenib monotherapy arm, the median PFS was 9.6 months (95% CI, 7.4-14.8 months) compared with encorafenib plus binimetinib (HR, 0.79; 95% CI, 0.61-1.02).